Literature DB >> 30894471

Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.

Min Zhuang1, Russell Vassell2, Chen Yuan3, Paul W Keller2, Hong Ling3, Wei Wang2, Carol D Weiss4.   

Abstract

Binding of the gp120 surface subunit of the envelope glycoprotein (Env) of HIV-1 to CD4 and chemokine receptors on target cells triggers refolding of the gp41 transmembrane subunit into a six-helix bundle (6HB) that promotes fusion between virus and host cell membranes. To elucidate details of Env entry and potential differences between viruses that use CXCR4 (X4) or CCR5 (R5) coreceptors, we generated viruses that are resistant to peptide fusion inhibitors corresponding to the first heptad repeat region (HR1) of gp41 that target fusion-intermediate conformations of Env. Previously we reported that an R5 virus selected two resistance pathways, each defined by an early gp41 resistance mutation in either HR1 or the second heptad repeat (HR2), to escape inhibition by an HR1 peptide, but preferentially selected the HR1 pathway to escape inhibition by a trimer-stabilized HR1 peptide. Here, we report that an X4 virus selected the same HR1 and HR2 resistance pathways as the R5 virus to escape inhibition by the HR1 peptide. However, in contrast to the R5 virus, the X4 virus selected a unique mutation in HR2 to escape inhibition by the trimer-stabilized peptide. Significantly, both of these X4 and R5 viruses acquired gp41 resistance mutations that improved the thermostability of the six-helix bundle, but they selected different gp120 adaptive mutations. These findings show that these X4 and R5 viruses use a similar resistance mechanism to escape from HR1 peptide inhibition but different gp120-gp41 interactions to regulate Env conformational changes.IMPORTANCE HIV-1 fuses with cells when the gp41 subunit of Env refolds into a 6HB after binding to cellular receptors. Peptides corresponding to HR1 or HR2 interrupt gp41 refolding and inhibit HIV infection. Previously, we found that a CCR5 coreceptor-tropic HIV-1 acquired a key HR1 or HR2 resistance mutation to escape HR1 peptide inhibitors but only the key HR1 mutation to escape a trimer-stabilized HR1 peptide inhibitor. Here, we report that a CXCR4 coreceptor-tropic HIV-1 selected the same key HR1 or HR2 mutations to escape inhibition by the HR1 peptide but different combinations of HR1 and HR2 mutations to escape the trimer-stabilized HR1 peptide. All gp41 mutations enhance 6HB stability to outcompete inhibitors, but gp120 adaptive mutations differed between these R5 and X4 viruses, providing new insights into gp120-gp41 functional interactions affecting Env refolding during HIV entry.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  HIV-1; conformational changes; fusion; fusion inhibitor; gp41; resistance

Mesh:

Substances:

Year:  2019        PMID: 30894471      PMCID: PMC6532104          DOI: 10.1128/JVI.00142-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Protein design of an HIV-1 entry inhibitor.

Authors:  M J Root; M S Kay; P S Kim
Journal:  Science       Date:  2001-02-02       Impact factor: 47.728

2.  Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.

Authors:  D M Eckert; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

3.  Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor.

Authors:  Eva Poveda; Berta Rodés; Carlos Toro; Luz Martín-Carbonero; Juan Gonzalez-Lahoz; Vincent Soriano
Journal:  AIDS       Date:  2002-09-27       Impact factor: 4.177

4.  Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope.

Authors:  Nicole R Kilgore; Karl Salzwedel; Mary Reddick; Graham P Allaway; Carl T Wild
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 5.  Resistance to enfuvirtide, the first HIV fusion inhibitor.

Authors:  Michael L Greenberg; Nick Cammack
Journal:  J Antimicrob Chemother       Date:  2004-07-01       Impact factor: 5.790

6.  The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions.

Authors:  Takumi Koshiba; David C Chan
Journal:  J Biol Chem       Date:  2002-12-13       Impact factor: 5.157

7.  Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein.

Authors:  Michael J Root; Dean H Hamer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

8.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

9.  Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41.

Authors:  Carole A Bewley; John M Louis; Rodolfo Ghirlando; G Marius Clore
Journal:  J Biol Chem       Date:  2002-02-21       Impact factor: 5.157

10.  Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites.

Authors:  Yong He; Russell Vassell; Marina Zaitseva; Nga Nguyen; Zhongning Yang; Yongkai Weng; Carol D Weiss
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more
  1 in total

1.  Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.

Authors:  Chen Yuan; Jia-Ye Wang; Hai-Jiao Zhao; Yan Li; Di Li; Hong Ling; Min Zhuang
Journal:  Retrovirology       Date:  2019-12-03       Impact factor: 4.602

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.